614 related articles for article (PubMed ID: 37498052)
1. Unveiling and harnessing the human gut microbiome in the rising burden of non-communicable diseases during urbanization.
Huang Z; Li Y; Park H; Ho M; Bhardwaj K; Sugimura N; Lee HW; Meng H; Ebert MP; Chao K; Burgermeister E; Bhatt AP; Shetty SA; Li K; Wen W; Zuo T
Gut Microbes; 2023; 15(1):2237645. PubMed ID: 37498052
[TBL] [Abstract][Full Text] [Related]
2. Different Strategies Targeting Gut Microbiota for the Management of Several Disorders: A Sustainable Approach.
Chowdhury M; Raj Chaudhary N; Kaur P; Goyal A; Sahu SK
Infect Disord Drug Targets; 2024; 24(5):e160124225675. PubMed ID: 38317473
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome-targeted therapies for Alzheimer's disease.
Zhang T; Gao G; Kwok LY; Sun Z
Gut Microbes; 2023 Dec; 15(2):2271613. PubMed ID: 37934614
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
Vemuri RC; Gundamaraju R; Shinde T; Eri R
Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
6. Microbiomes in physiology: insights into 21st-century global medical challenges.
Shehata E; Parker A; Suzuki T; Swann JR; Suez J; Kroon PA; Day-Walsh P
Exp Physiol; 2022 Apr; 107(4):257-264. PubMed ID: 35081663
[TBL] [Abstract][Full Text] [Related]
7. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases.
Noce A; Marrone G; Di Daniele F; Ottaviani E; Wilson Jones G; Bernini R; Romani A; Rovella V
Nutrients; 2019 May; 11(5):. PubMed ID: 31091761
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Haak BW; Prescott HC; Wiersinga WJ
Front Immunol; 2018; 9():2042. PubMed ID: 30250472
[TBL] [Abstract][Full Text] [Related]
9. Anorexia nervosa and gut microbiome: implications for weight change and novel treatments.
Wei Y; Peng S; Lian C; Kang Q; Chen J
Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):321-332. PubMed ID: 35303781
[TBL] [Abstract][Full Text] [Related]
10. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications.
Cuevas-Sierra A; Ramos-Lopez O; Riezu-Boj JI; Milagro FI; Martinez JA
Adv Nutr; 2019 Jan; 10(suppl_1):S17-S30. PubMed ID: 30721960
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.
Sorboni SG; Moghaddam HS; Jafarzadeh-Esfehani R; Soleimanpour S
Clin Microbiol Rev; 2022 Jan; 35(1):e0033820. PubMed ID: 34985325
[TBL] [Abstract][Full Text] [Related]
12. Restoration of dysbiotic human gut microbiome for homeostasis.
Dixit K; Chaudhari D; Dhotre D; Shouche Y; Saroj S
Life Sci; 2021 Aug; 278():119622. PubMed ID: 34015282
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota: a target for intervention in obesity.
Sehgal K; Khanna S
Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1169-1179. PubMed ID: 34329563
[TBL] [Abstract][Full Text] [Related]
14. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care.
Ciernikova S; Sevcikova A; Drgona L; Mego M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188990. PubMed ID: 37742728
[TBL] [Abstract][Full Text] [Related]
15. Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?
Amedei A; Capasso C; Nannini G; Supuran CT
Mediators Inflamm; 2021; 2021():6926082. PubMed ID: 34803517
[TBL] [Abstract][Full Text] [Related]
16. Role of Microbiome and Antibiotics in Autoimmune Diseases.
Vangoitsenhoven R; Cresci GAM
Nutr Clin Pract; 2020 Jun; 35(3):406-416. PubMed ID: 32319703
[TBL] [Abstract][Full Text] [Related]
17. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
18. Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
Kapoor B; Gulati M; Gupta R; Singla RK
Autoimmun Rev; 2023 May; 22(5):103313. PubMed ID: 36918089
[TBL] [Abstract][Full Text] [Related]
19. Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis.
Kujawa D; Laczmanski L; Budrewicz S; Pokryszko-Dragan A; Podbielska M
Gut Microbes; 2023 Dec; 15(2):2274126. PubMed ID: 37979154
[TBL] [Abstract][Full Text] [Related]
20. The role of the gut microbiota in the treatment of inflammatory bowel diseases.
Aggeletopoulou I; Konstantakis C; Assimakopoulos SF; Triantos C
Microb Pathog; 2019 Dec; 137():103774. PubMed ID: 31586663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
